Abstract
Immune checkpoint inhibitors have shown therapeutic efficacy in various malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown clinical efficacy in multiple myeloma (MM). To enhance the clinical efficacy of immune checkpoint blockade in MM, elaborate characterization of tumor (myeloma) antigen-specific T cells is an essential prerequisite. In addition, the role of immunosuppressive factors abundant in the bone marrow (BM) of MM patients need to be considered.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
